Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a pilot study to investigate the safety and tolerability of rhDNase1 and its impact on neutrophil extracellular traps (NETs) in COVID-19 infected patients
Description: Time to first study participant enrolment is defined as the time elapsed between the study opening date and the first patient enrolment date.
Measure: Time to first study participant enrolment Time: Up to 2 weeksDescription: Enrolment rate is defined as the number of patients enrolled per week following the start of the study.
Measure: Enrolment rate Time: Up to 9 monthsDescription: Eligible patient consent rate is defined as the number of patients meeting eligibility through inclusion and exclusion criteria that are consented and enrolled into the study.
Measure: Eligible patient consent rate Time: Up to 9 monthsDescription: The percentage of doses missed compared to completed, including reasons for missed doses, per patient.
Measure: Completeness of drug delivery Time: Up to 9 monthsDescription: The percentage of tests or procedures missed compared to completed, per patient.
Measure: Completeness of study-specific tests or procedures Time: Up to 9 monthsDescription: The percentage of missing data compared to completed data, per patient.
Measure: Completeness of data collection Time: Up to 9 monthsDescription: Extent of hypoxia rate is defined as the number of patients requiring supplemental oxygen, categorized by type of oxygen requirement.
Measure: Hypoxia rate Time: Up to 9 monthsDescription: The type of oxygen in FiO2 requirements needed by each patient in the study, if applicable.
Measure: Supplemental oxygen requirement type Time: Up to 9 monthsDescription: Number of patients progressing to requiring intubation and mechanical ventilation.
Measure: Progression to mechanical ventilation rate Time: Up to 9 monthsDescription: Duration in days, for patients requiring intubation and mechanical ventilation, if applicable.
Measure: Duration of mechanical ventilation Time: Up to 9 monthsDescription: Number of patients who show progression on imaging suggestive of ARDS such as bilateral lung involvement, as reviewed by study's thoracic radiologist.
Measure: Radiological progression Time: Up to 9 monthsDescription: Number of patients with renal dysfunction, classified by stage (1, 2 or 3).
Measure: Renal dysfunction rate Time: Up to 9 monthsDescription: Extent of change in creatinine from baseline.
Measure: Renal dysfunction extent Time: Up to 9 monthsDescription: Time to hospital discharge of in-hospital mortality is defined as the time elapsed between enrolment into the study (at admission), and endpoint (discharge or in-hospital mortality).
Measure: Time to hospital discharge or in-hospital mortality Time: Up to 9 monthsDescription: Number of health care workers in direct contact with study participants and developing a COVID-19 infection.
Measure: Overall safety of health care workers and study personnel Time: Up to 9 monthsDescription: Number of times per day a health care worker enters each study participant's room.
Measure: Daily safety of health care workers and study Time: Up to 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports